From the Departments of Radiology (K. Hee Lee, J.H.P., Y.H.K., K.W.L., J.K., K. Ho Lee), Internal Medicine (J.W.K., H.Y.), and Surgery (H.K.O.), Seoul National University Bundang Hospital, Seoul National University College of Medicine, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do 13620, Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea (Y.H.K., K.W.L.); Department of Statistics, University of Seoul, Seoul, Korea (J.J.J.); and Program in Biomedical Radiation Sciences, Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology Seoul National University, Seoul, Korea (K. Ho Lee).
Radiology. 2018 Nov;289(2):535-545. doi: 10.1148/radiol.2018180009. Epub 2018 Aug 7.
Purpose To measure the diagnostic yield and false-referral rate (FRR) of staging contrast material-enhanced chest CT based on the clinical stage from contrast-enhanced abdominal CT in patients with colon cancer. Materials and Methods This retrospective study included 1743 patients (mean age, 63.4 years; range, 18-96 years) with a diagnosis of colon cancer. The primary outcomes were diagnostic yield and FRR of contrast-enhanced chest CT in the detection of thoracic metastasis. The proportions of patients with occult thoracic metastasis and those undergoing pulmonary metastasectomy for true-positive metastases were key secondary outcomes. The outcomes were stratified according to clinical stage at contrast-enhanced abdominal CT. Results The diagnostic yields in clinical stage 0/I, cII, cIII, and cIV were 0% (95% confidence interval [CI]: 0%, 0.8%), 1.3% (95% CI: 0.4%, 3.3%), 4.4% (95% CI: 3.0%, 6.1%), and 43.3% (95% CI: 36.8%, 49.9%), respectively. The corresponding FRRs were 5.7% (95% CI: 3.8%, 8.2%), 2.9% (95% CI: 1.3%, 5.5%), 6.7% (95% CI: 5.0%, 8.8%), and 6.1% (95% CI: 3.4%, 10.0%), respectively. The proportions of patients with occult metastasis were 0% (95% CI: 0%, 0.8%), 3.3% (95% CI: 1.6%, 5.9%), 1.5% (95% CI: 0.8%, 2.7%), and 6.1% (95% CI: 3.4%, 10.0%), respectively. The proportion of patients who underwent pulmonary metastasectomy was 0% (none of 474; 95% CI: 0%, 0.8%) for clinical stage 0/I tumors. Conclusion In clinical stages 0 and I, the diagnostic yield of staging contrast-enhanced chest CT in detecting thoracic metastasis was zero. For clinical stages II, III, and IV, contrast-enhanced chest CT as a baseline examination was helpful for the detection of thoracic metastasis and allowed for the possibility of a curative metastasectomy. There was no significant association between clinical stage and false-referral rate. © RSNA, 2018 Online supplemental material is available for this article.
目的 基于增强腹部 CT 的临床分期,评估结直肠癌患者分期对比增强胸部 CT 的诊断检出率和假阳性转诊率(FRR)。
材料与方法 本回顾性研究纳入 1743 例经诊断为结肠癌的患者(平均年龄,63.4 岁;范围,18~96 岁)。主要结局为检测胸部转移时,增强胸部 CT 的诊断检出率和 FRR。隐匿性胸部转移患者的比例和经手术证实的阳性转移患者行肺转移切除术的比例为次要关键结局。根据增强腹部 CT 的临床分期对结局进行分层。
结果 在临床分期 0 期/I 期、cII 期、cIII 期和 cIV 期,诊断检出率分别为 0%(95%CI:0%,0.8%)、1.3%(95%CI:0.4%,3.3%)、4.4%(95%CI:3.0%,6.1%)和 43.3%(95%CI:36.8%,49.9%),相应的 FRR 分别为 5.7%(95%CI:3.8%,8.2%)、2.9%(95%CI:1.3%,5.5%)、6.7%(95%CI:5.0%,8.8%)和 6.1%(95%CI:3.4%,10.0%)。隐匿性转移患者的比例分别为 0%(95%CI:0%,0.8%)、3.3%(95%CI:1.6%,5.9%)、1.5%(95%CI:0.8%,2.7%)和 6.1%(95%CI:3.4%,10.0%)。行肺转移切除术的患者比例分别为 0%(474 例均无;95%CI:0%,0.8%)、3.3%(95%CI:1.6%,5.9%)、1.5%(95%CI:0.8%,2.7%)和 6.1%(95%CI:3.4%,10.0%)。
结论 在临床分期 0 期和 I 期,增强胸部 CT 检测胸部转移的诊断检出率为 0。对于临床分期 II、III 和 IV 期,增强胸部 CT 作为基线检查有助于检测胸部转移,并可能进行治愈性转移切除术。临床分期与 FRR 之间无显著相关性。
© 2018 RSNA,在线补充材料可供本文参考。